| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 103 | 2024 | 848 | 22.300 |
Why?
|
| Diabetes Mellitus, Type 2 | 27 | 2024 | 1412 | 6.760 |
Why?
|
| Autoantibodies | 36 | 2024 | 602 | 5.630 |
Why?
|
| Islets of Langerhans | 19 | 2024 | 236 | 4.730 |
Why?
|
| C-Peptide | 21 | 2024 | 122 | 3.620 |
Why?
|
| Insulin Resistance | 8 | 2023 | 732 | 3.060 |
Why?
|
| Insulin | 26 | 2024 | 1483 | 2.420 |
Why?
|
| Diabetic Ketoacidosis | 10 | 2024 | 160 | 2.240 |
Why?
|
| Autoimmunity | 13 | 2020 | 267 | 1.970 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 6 | 2022 | 40 | 1.930 |
Why?
|
| Blood Glucose | 17 | 2024 | 1269 | 1.770 |
Why?
|
| Hypoglycemic Agents | 11 | 2023 | 599 | 1.600 |
Why?
|
| Insulin-Secreting Cells | 7 | 2024 | 160 | 1.580 |
Why?
|
| Child | 67 | 2024 | 30559 | 1.410 |
Why?
|
| Adolescent | 61 | 2024 | 32767 | 1.400 |
Why?
|
| Diabetes Complications | 2 | 2023 | 300 | 1.310 |
Why?
|
| Glutamate Decarboxylase | 6 | 2017 | 48 | 1.170 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2022 | 4644 | 1.140 |
Why?
|
| Glucose Tolerance Test | 7 | 2022 | 214 | 1.090 |
Why?
|
| Genetic Heterogeneity | 3 | 2018 | 338 | 1.080 |
Why?
|
| Child, Preschool | 38 | 2024 | 17061 | 1.020 |
Why?
|
| Hypoglycemia | 6 | 2018 | 220 | 0.940 |
Why?
|
| Humans | 125 | 2024 | 270740 | 0.910 |
Why?
|
| Genetic Predisposition to Disease | 17 | 2022 | 5776 | 0.890 |
Why?
|
| Puberty | 2 | 2021 | 97 | 0.850 |
Why?
|
| Body Mass Index | 10 | 2023 | 2232 | 0.850 |
Why?
|
| HLA-DQ Antigens | 6 | 2018 | 56 | 0.830 |
Why?
|
| Leptin | 2 | 2023 | 306 | 0.830 |
Why?
|
| Minority Groups | 3 | 2020 | 328 | 0.790 |
Why?
|
| Pediatric Obesity | 5 | 2021 | 376 | 0.780 |
Why?
|
| Disease Progression | 18 | 2022 | 6867 | 0.740 |
Why?
|
| Obesity | 10 | 2022 | 2904 | 0.740 |
Why?
|
| Genetic Linkage | 2 | 2021 | 603 | 0.730 |
Why?
|
| Hyperglycemia | 4 | 2020 | 337 | 0.710 |
Why?
|
| Diabetes, Gestational | 1 | 2022 | 116 | 0.700 |
Why?
|
| Male | 67 | 2024 | 128315 | 0.670 |
Why?
|
| Metformin | 1 | 2023 | 393 | 0.660 |
Why?
|
| Diagnostic Errors | 1 | 2024 | 518 | 0.660 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 550 | 0.650 |
Why?
|
| Female | 68 | 2024 | 148940 | 0.640 |
Why?
|
| Flatfishes | 3 | 2006 | 3 | 0.610 |
Why?
|
| Fish Diseases | 3 | 2006 | 14 | 0.600 |
Why?
|
| Overweight | 7 | 2020 | 484 | 0.600 |
Why?
|
| Risk Factors | 20 | 2024 | 17888 | 0.590 |
Why?
|
| Infant | 21 | 2021 | 13999 | 0.590 |
Why?
|
| Age of Onset | 6 | 2020 | 853 | 0.580 |
Why?
|
| Adiposity | 2 | 2020 | 238 | 0.570 |
Why?
|
| Diabetes Mellitus | 4 | 2024 | 1024 | 0.560 |
Why?
|
| Osteocalcin | 1 | 2017 | 88 | 0.550 |
Why?
|
| Protozoan Infections, Animal | 2 | 2006 | 3 | 0.550 |
Why?
|
| Young Adult | 20 | 2024 | 22251 | 0.540 |
Why?
|
| Prediabetic State | 3 | 2015 | 64 | 0.540 |
Why?
|
| Twins, Monozygotic | 3 | 2008 | 136 | 0.530 |
Why?
|
| Phenotype | 9 | 2024 | 6509 | 0.520 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 602 | 0.510 |
Why?
|
| Cross-Sectional Studies | 6 | 2024 | 4492 | 0.500 |
Why?
|
| Hospitalization | 1 | 2024 | 2167 | 0.490 |
Why?
|
| Diseases in Twins | 2 | 2008 | 110 | 0.480 |
Why?
|
| Cohort Studies | 16 | 2020 | 9470 | 0.480 |
Why?
|
| Adult | 33 | 2024 | 82040 | 0.450 |
Why?
|
| Thinness | 1 | 2014 | 79 | 0.450 |
Why?
|
| Prospective Studies | 15 | 2024 | 13414 | 0.430 |
Why?
|
| Biomarkers | 6 | 2024 | 5051 | 0.430 |
Why?
|
| Precision Medicine | 4 | 2024 | 1207 | 0.410 |
Why?
|
| Glucose | 5 | 2023 | 1218 | 0.390 |
Why?
|
| Health Personnel | 1 | 2017 | 652 | 0.380 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 901 | 0.360 |
Why?
|
| Eukaryota | 2 | 2006 | 28 | 0.330 |
Why?
|
| Socioeconomic Factors | 5 | 2018 | 1267 | 0.330 |
Why?
|
| Patient Preference | 1 | 2011 | 229 | 0.320 |
Why?
|
| Antibody Specificity | 3 | 2018 | 336 | 0.320 |
Why?
|
| Zinc Transporter 8 | 3 | 2017 | 6 | 0.310 |
Why?
|
| Age Factors | 9 | 2020 | 5457 | 0.310 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 5 | 2017 | 12 | 0.300 |
Why?
|
| Prevalence | 6 | 2024 | 3404 | 0.300 |
Why?
|
| Twins, Dizygotic | 2 | 2004 | 48 | 0.280 |
Why?
|
| Social Class | 2 | 2020 | 324 | 0.270 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 831 | 0.270 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2006 | 43 | 0.260 |
Why?
|
| Dyslipidemias | 2 | 2021 | 241 | 0.260 |
Why?
|
| Major Histocompatibility Complex | 4 | 2017 | 99 | 0.260 |
Why?
|
| Health Status Disparities | 2 | 2020 | 318 | 0.250 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 2224 | 0.240 |
Why?
|
| Insulin Infusion Systems | 3 | 2016 | 58 | 0.240 |
Why?
|
| Prognosis | 7 | 2024 | 22505 | 0.230 |
Why?
|
| Cluster Analysis | 2 | 2024 | 1075 | 0.230 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2022 | 73 | 0.220 |
Why?
|
| Weight Gain | 3 | 2017 | 471 | 0.220 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 2 | 2022 | 74 | 0.220 |
Why?
|
| Fabaceae | 1 | 2023 | 31 | 0.210 |
Why?
|
| HLA-DRB1 Chains | 3 | 2017 | 89 | 0.210 |
Why?
|
| Siblings | 1 | 2004 | 319 | 0.210 |
Why?
|
| Alleles | 5 | 2017 | 2600 | 0.200 |
Why?
|
| Acanthosis Nigricans | 1 | 2022 | 15 | 0.200 |
Why?
|
| Self-Management | 2 | 2020 | 105 | 0.200 |
Why?
|
| HLA-DR Antigens | 2 | 2005 | 184 | 0.190 |
Why?
|
| Celiac Disease | 2 | 2017 | 77 | 0.190 |
Why?
|
| Middle Aged | 17 | 2024 | 90352 | 0.190 |
Why?
|
| Immunity, Innate | 1 | 2006 | 699 | 0.190 |
Why?
|
| Genetic Vectors | 2 | 2017 | 1857 | 0.190 |
Why?
|
| Immune System | 2 | 2020 | 275 | 0.190 |
Why?
|
| Latent Autoimmune Diabetes in Adults | 1 | 2020 | 2 | 0.190 |
Why?
|
| Haplotypes | 6 | 2020 | 910 | 0.180 |
Why?
|
| Sex Characteristics | 2 | 2020 | 425 | 0.180 |
Why?
|
| Interleukin-4 | 2 | 2005 | 290 | 0.180 |
Why?
|
| Blood Glucose Self-Monitoring | 3 | 2020 | 116 | 0.170 |
Why?
|
| HLA-DR2 Antigen | 1 | 1999 | 11 | 0.170 |
Why?
|
| Antibodies, Heterophile | 1 | 1999 | 9 | 0.170 |
Why?
|
| HLA-DQ alpha-Chains | 4 | 2017 | 23 | 0.170 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 27 | 0.170 |
Why?
|
| Genotype | 5 | 2018 | 4252 | 0.170 |
Why?
|
| Genes, MHC Class II | 1 | 1999 | 71 | 0.170 |
Why?
|
| Sex Factors | 5 | 2017 | 2184 | 0.170 |
Why?
|
| Gene-Environment Interaction | 1 | 2020 | 163 | 0.170 |
Why?
|
| Early Diagnosis | 1 | 2021 | 313 | 0.170 |
Why?
|
| United States | 9 | 2020 | 15861 | 0.170 |
Why?
|
| Models, Immunological | 2 | 2015 | 79 | 0.160 |
Why?
|
| Prescription Drugs | 1 | 2020 | 61 | 0.160 |
Why?
|
| Global Health | 1 | 2024 | 692 | 0.160 |
Why?
|
| Healthcare Disparities | 2 | 2016 | 657 | 0.160 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2018 | 20 | 0.160 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2020 | 182 | 0.150 |
Why?
|
| Cation Transport Proteins | 2 | 2017 | 170 | 0.150 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 436 | 0.150 |
Why?
|
| Chromosome Mapping | 1 | 2002 | 1655 | 0.150 |
Why?
|
| Cytokines | 2 | 2014 | 2825 | 0.150 |
Why?
|
| Electronic Health Records | 1 | 2024 | 850 | 0.140 |
Why?
|
| Family | 2 | 2017 | 783 | 0.140 |
Why?
|
| Spain | 4 | 2007 | 100 | 0.140 |
Why?
|
| Registries | 4 | 2022 | 2211 | 0.140 |
Why?
|
| Leg | 1 | 1997 | 213 | 0.140 |
Why?
|
| Follow-Up Studies | 7 | 2016 | 15218 | 0.140 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 411 | 0.130 |
Why?
|
| Cultural Characteristics | 1 | 2016 | 66 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 185 | 0.130 |
Why?
|
| Diabetic Foot | 1 | 1997 | 127 | 0.130 |
Why?
|
| Mass Screening | 2 | 2022 | 1552 | 0.130 |
Why?
|
| Glucagon | 1 | 2016 | 201 | 0.130 |
Why?
|
| Nutritional Sciences | 1 | 2016 | 68 | 0.130 |
Why?
|
| Retroviridae | 1 | 2016 | 373 | 0.130 |
Why?
|
| Longitudinal Studies | 4 | 2019 | 2057 | 0.130 |
Why?
|
| Child Development | 1 | 2017 | 266 | 0.130 |
Why?
|
| Immunotherapy | 2 | 2024 | 3557 | 0.130 |
Why?
|
| Gene Frequency | 1 | 2018 | 1246 | 0.130 |
Why?
|
| Acculturation | 1 | 2016 | 110 | 0.120 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 118 | 0.120 |
Why?
|
| Pandemics | 1 | 2024 | 1610 | 0.120 |
Why?
|
| Perception | 1 | 2017 | 349 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 625 | 0.120 |
Why?
|
| Health Literacy | 1 | 2016 | 117 | 0.120 |
Why?
|
| Communication | 2 | 2019 | 839 | 0.120 |
Why?
|
| Genetic Testing | 2 | 2017 | 1696 | 0.120 |
Why?
|
| Exercise | 1 | 2022 | 1184 | 0.120 |
Why?
|
| Histocompatibility Testing | 3 | 2001 | 487 | 0.120 |
Why?
|
| Seasons | 2 | 2006 | 337 | 0.110 |
Why?
|
| Cloning, Molecular | 1 | 2016 | 1430 | 0.110 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 159 | 0.110 |
Why?
|
| Adipokines | 1 | 2014 | 97 | 0.110 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 4960 | 0.110 |
Why?
|
| Language | 1 | 2016 | 326 | 0.110 |
Why?
|
| Nuclear Family | 1 | 2013 | 68 | 0.110 |
Why?
|
| Qualitative Research | 1 | 2017 | 642 | 0.110 |
Why?
|
| Epitopes | 1 | 2016 | 707 | 0.110 |
Why?
|
| Gene Transfer Techniques | 1 | 2016 | 804 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2024 | 39890 | 0.110 |
Why?
|
| Lignans | 1 | 2012 | 14 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 3409 | 0.100 |
Why?
|
| Infant, Newborn | 5 | 2020 | 8699 | 0.100 |
Why?
|
| Poverty | 1 | 2016 | 486 | 0.100 |
Why?
|
| Insulin Antibodies | 3 | 2017 | 7 | 0.100 |
Why?
|
| Pancreas, Artificial | 1 | 2011 | 3 | 0.100 |
Why?
|
| Time Factors | 5 | 2016 | 13006 | 0.100 |
Why?
|
| Self Administration | 1 | 2011 | 58 | 0.100 |
Why?
|
| Twin Studies as Topic | 2 | 2001 | 20 | 0.100 |
Why?
|
| Flavonoids | 1 | 2012 | 199 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 1137 | 0.090 |
Why?
|
| Polymorphism, Genetic | 4 | 2015 | 1557 | 0.090 |
Why?
|
| Inflammation | 1 | 2020 | 2518 | 0.090 |
Why?
|
| Random Allocation | 2 | 2016 | 741 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 2012 | 368 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 600 | 0.090 |
Why?
|
| Pedigree | 3 | 2021 | 2042 | 0.090 |
Why?
|
| Aquaculture | 2 | 2006 | 6 | 0.080 |
Why?
|
| Aging | 1 | 2017 | 1534 | 0.080 |
Why?
|
| Diet | 2 | 2012 | 1477 | 0.080 |
Why?
|
| Stem Cells | 1 | 2016 | 1216 | 0.080 |
Why?
|
| HLA-DQ beta-Chains | 2 | 2017 | 34 | 0.080 |
Why?
|
| Area Under Curve | 2 | 2024 | 729 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 1418 | 0.080 |
Why?
|
| Pregnancy | 1 | 2022 | 8130 | 0.080 |
Why?
|
| Mental Disorders | 1 | 2016 | 882 | 0.080 |
Why?
|
| Autoantigens | 2 | 2001 | 248 | 0.080 |
Why?
|
| Antigen-Presenting Cells | 2 | 2015 | 286 | 0.070 |
Why?
|
| Risk | 3 | 2017 | 1939 | 0.070 |
Why?
|
| Body Weight | 2 | 2015 | 1307 | 0.070 |
Why?
|
| Calpain | 1 | 2007 | 70 | 0.070 |
Why?
|
| Immunity, Active | 1 | 2006 | 14 | 0.070 |
Why?
|
| alpha-Macroglobulins | 1 | 2006 | 10 | 0.070 |
Why?
|
| HLA Antigens | 2 | 2016 | 594 | 0.070 |
Why?
|
| Quality of Life | 1 | 2021 | 4761 | 0.070 |
Why?
|
| Complement Pathway, Alternative | 1 | 2006 | 16 | 0.070 |
Why?
|
| Muramidase | 1 | 2006 | 113 | 0.070 |
Why?
|
| Life Tables | 1 | 2006 | 120 | 0.070 |
Why?
|
| Spleen | 2 | 2006 | 726 | 0.070 |
Why?
|
| Pediatrics | 1 | 2015 | 1186 | 0.060 |
Why?
|
| Blood Cells | 1 | 2006 | 129 | 0.060 |
Why?
|
| Animals | 10 | 2017 | 61956 | 0.060 |
Why?
|
| Hypertension | 1 | 2015 | 1591 | 0.060 |
Why?
|
| Depression | 1 | 2015 | 1730 | 0.060 |
Why?
|
| Granulocytes | 1 | 2006 | 244 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2006 | 203 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2006 | 206 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2023 | 2828 | 0.060 |
Why?
|
| Cryptosporidium | 1 | 2004 | 49 | 0.060 |
Why?
|
| Family Health | 2 | 2005 | 349 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 3949 | 0.060 |
Why?
|
| Racemethionine | 1 | 2023 | 6 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 5101 | 0.060 |
Why?
|
| Laryngeal Neoplasms | 1 | 2007 | 529 | 0.050 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 4328 | 0.050 |
Why?
|
| Drug Monitoring | 2 | 2016 | 352 | 0.050 |
Why?
|
| Methionine | 1 | 2023 | 170 | 0.050 |
Why?
|
| Liraglutide | 1 | 2022 | 16 | 0.050 |
Why?
|
| Incidence | 3 | 2013 | 5824 | 0.050 |
Why?
|
| Citrulline | 1 | 2023 | 113 | 0.050 |
Why?
|
| Mice, Inbred NOD | 3 | 2016 | 896 | 0.050 |
Why?
|
| Mesonephroma | 1 | 2001 | 17 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2024 | 33737 | 0.050 |
Why?
|
| Europe | 2 | 2013 | 658 | 0.050 |
Why?
|
| Papilloma | 1 | 2001 | 86 | 0.050 |
Why?
|
| Self Tolerance | 1 | 2001 | 18 | 0.050 |
Why?
|
| Glutamine | 1 | 2023 | 324 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2001 | 190 | 0.050 |
Why?
|
| Frameshift Mutation | 1 | 2021 | 234 | 0.040 |
Why?
|
| Aza Compounds | 1 | 2000 | 25 | 0.040 |
Why?
|
| United Kingdom | 1 | 2001 | 287 | 0.040 |
Why?
|
| Streptococcus | 1 | 2000 | 79 | 0.040 |
Why?
|
| Vaginal Neoplasms | 1 | 2001 | 152 | 0.040 |
Why?
|
| Oxazolidinones | 1 | 2000 | 63 | 0.040 |
Why?
|
| Stomach Neoplasms | 1 | 2012 | 2331 | 0.040 |
Why?
|
| Arginine | 1 | 2023 | 507 | 0.040 |
Why?
|
| Body Composition | 2 | 2013 | 606 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2001 | 311 | 0.040 |
Why?
|
| Fluoroquinolones | 1 | 2000 | 135 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 627 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 122 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 1106 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2023 | 1034 | 0.040 |
Why?
|
| CTLA-4 Antigen | 2 | 2017 | 678 | 0.040 |
Why?
|
| Artificial Limbs | 1 | 1997 | 8 | 0.040 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 1998 | 76 | 0.040 |
Why?
|
| Receptors, CCR7 | 1 | 2017 | 38 | 0.040 |
Why?
|
| Pineal Gland | 1 | 1997 | 43 | 0.040 |
Why?
|
| Pinealoma | 1 | 1997 | 50 | 0.040 |
Why?
|
| Germinoma | 1 | 1997 | 82 | 0.040 |
Why?
|
| Anthropometry | 1 | 2018 | 262 | 0.040 |
Why?
|
| Kidney | 1 | 2006 | 2121 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2020 | 397 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2017 | 6224 | 0.040 |
Why?
|
| Quinolines | 1 | 2000 | 402 | 0.030 |
Why?
|
| Parenteral Nutrition | 1 | 1998 | 213 | 0.030 |
Why?
|
| Learning | 1 | 2020 | 431 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 59 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1997 | 310 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2001 | 1163 | 0.030 |
Why?
|
| ROC Curve | 1 | 2020 | 1248 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 2345 | 0.030 |
Why?
|
| Medical Records | 1 | 1997 | 442 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2020 | 676 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2021 | 1192 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 2650 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 342 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 1129 | 0.030 |
Why?
|
| Pituitary Neoplasms | 1 | 1997 | 216 | 0.030 |
Why?
|
| Aged | 6 | 2013 | 73333 | 0.030 |
Why?
|
| Comorbidity | 1 | 2022 | 2394 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 293 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2016 | 494 | 0.030 |
Why?
|
| Cell Separation | 1 | 2016 | 609 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2015 | 164 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2006 | 9292 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 919 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1997 | 557 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 7914 | 0.030 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2013 | 65 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2021 | 2166 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 681 | 0.030 |
Why?
|
| Cell Line | 1 | 2000 | 5338 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2013 | 106 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 1461 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 5923 | 0.030 |
Why?
|
| DNA | 1 | 2000 | 3050 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 4831 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 661 | 0.020 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 617 | 0.020 |
Why?
|
| Neoplasms | 2 | 2013 | 15927 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 1281 | 0.020 |
Why?
|
| Transfection | 1 | 2016 | 3117 | 0.020 |
Why?
|
| Mice | 4 | 2017 | 35600 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 2001 | 2928 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2017 | 1624 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 1470 | 0.020 |
Why?
|
| Cause of Death | 1 | 2013 | 789 | 0.020 |
Why?
|
| Length of Stay | 1 | 1997 | 2007 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 5162 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 1051 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 3597 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2001 | 13 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2017 | 1718 | 0.020 |
Why?
|
| Proteins | 1 | 2017 | 2043 | 0.020 |
Why?
|
| Life Style | 1 | 2012 | 618 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2001 | 10265 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 4223 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 5056 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2000 | 3187 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 1184 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 3891 | 0.020 |
Why?
|
| Survival Rate | 1 | 1999 | 12541 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4372 | 0.020 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2005 | 21 | 0.020 |
Why?
|
| Israel | 1 | 2005 | 62 | 0.020 |
Why?
|
| Arabs | 1 | 2005 | 33 | 0.020 |
Why?
|
| Jews | 1 | 2005 | 57 | 0.020 |
Why?
|
| Oocysts | 1 | 2004 | 7 | 0.020 |
Why?
|
| Atlantic Ocean | 1 | 2004 | 5 | 0.020 |
Why?
|
| Interleukin-13 | 1 | 2005 | 130 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 6764 | 0.020 |
Why?
|
| Histological Techniques | 1 | 2004 | 63 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2005 | 247 | 0.010 |
Why?
|
| Glutens | 1 | 2004 | 10 | 0.010 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2004 | 239 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 5002 | 0.010 |
Why?
|
| Transglutaminases | 1 | 2004 | 97 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6256 | 0.010 |
Why?
|
| Species Specificity | 1 | 2004 | 794 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 2004 | 271 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2017 | 5438 | 0.010 |
Why?
|
| Denmark | 1 | 2001 | 55 | 0.010 |
Why?
|
| Virus Diseases | 1 | 2005 | 393 | 0.010 |
Why?
|
| Clonal Deletion | 1 | 2001 | 7 | 0.010 |
Why?
|
| Proinsulin | 1 | 2001 | 14 | 0.010 |
Why?
|
| Virginiamycin | 1 | 2000 | 14 | 0.010 |
Why?
|
| Erythromycin | 1 | 2000 | 23 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 1997 | 4958 | 0.010 |
Why?
|
| Linezolid | 1 | 2000 | 71 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 2315 | 0.010 |
Why?
|
| Oxazoles | 1 | 2000 | 61 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 1418 | 0.010 |
Why?
|
| Naphthyridines | 1 | 2000 | 45 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2000 | 243 | 0.010 |
Why?
|
| Acetamides | 1 | 2000 | 111 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2001 | 1189 | 0.010 |
Why?
|
| Epithelium | 1 | 2001 | 782 | 0.010 |
Why?
|
| Vagina | 1 | 2001 | 331 | 0.010 |
Why?
|
| Environment | 1 | 2000 | 172 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2004 | 1105 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2000 | 1076 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2001 | 1275 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1998 | 16689 | 0.010 |
Why?
|
| Triglycerides | 1 | 1998 | 611 | 0.010 |
Why?
|
| Gene Expression | 1 | 2001 | 3640 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2001 | 3077 | 0.010 |
Why?
|
| Apoptosis | 1 | 2001 | 7757 | 0.000 |
Why?
|
| Biomarkers, Tumor | 1 | 2001 | 10708 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1997 | 7895 | 0.000 |
Why?
|